S&P lowers U.S. Renal Care view to negative

Standard & Poor's said it affirmed the B corporate credit rating on U.S. Renal Care Inc. and revised the outlook to negative from stable.

These actions reflect the company's planned debt-financed acquisition of Ambulatory Services of America.

The agency also said it placed the B+ rating on the company's first-lien debt on CreditWatch with negative implications because the size of this debt class may increase relative to the estimate of the enterprise's value in the event of default.

S&P also said it affirmed the CCC+ rating on the company's second-lien debt with a recovery rating on the first-lien debt is 2, indicating 70% to 90% expected default recovery.

The recovery rating on the second-lien debt is 6, indicating 0 to 10% expected default recovery.

The ratings continue to reflect its vulnerable business risk profile, distinguished by its dependence on the treatment of a single disease, pressure from third-party payors to reduce payments, unfavorable payor profile with a heavy reliance on Medicare and still relatively small scale, the agency said.

The company's planned debt-financed acquisition of Ambulatory Services of America will roughly double the company's size and substantially increase its debt burden, S&P said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.